Perrigo Reaches 5-Day High Amid Class Action Lawsuit News
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 19 2025
0mins
Should l Buy PRGO?
Source: Globenewswire
Perrigo Company PLC's stock rose by 5.02%, reaching a 5-day high. This increase comes despite broader market declines, with the Nasdaq-100 down 0.31% and the S&P 500 down 0.37%.
The rise in Perrigo's stock is linked to recent news regarding a class action lawsuit filed against the company for allegedly misleading investors about its financial health and operational issues following its acquisition of Nestlé's infant formula business. The lawsuit claims that Perrigo failed to disclose significant underinvestment and manufacturing deficiencies, which has raised concerns among investors.
This legal challenge could have implications for Perrigo's reputation and financial stability, as investors seek damages for losses incurred during the period in question. The outcome of the lawsuit may influence future investor confidence and stock performance.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PRGO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PRGO
Wall Street analysts forecast PRGO stock price to rise
3 Analyst Rating
1 Buy
2 Hold
0 Sell
Moderate Buy
Current: 14.440
Low
18.00
Averages
20.33
High
23.00
Current: 14.440
Low
18.00
Averages
20.33
High
23.00
About PRGO
Perrigo Company plc is a provider of over the counter (OTC) health and wellness solutions that are designed to enhance individual well-being. Its segments include Consumer Self-Care Americas (CSCA) and Consumer Self-Care International (CSCI). The CSCA segment comprises of its consumer self-care business in the United States and Canada. It primarily provides its customers self-care products that are sold and marketed under the customer's own brands and/or exclusive brands. The CSCI segment comprises of its consumer self-care business outside of the United States and Canada, primarily in Europe and Australia. These products are developed, manufactured, marketed, and distributed by the Company. Its product categories include Upper Respiratory, Pain and Sleep-Aids, Skincare and Personal Hygiene, Digestive Health, and Nutrition. Its primary branded products are sold under brand names Compeed, Dr. Fresh, Firefly, Good Sense, Mederma, Nasonex, Solpadeine, Coldrex, and Physiomer, among others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
FDA Pushes for Prescription Drugs to Become Over-the-Counter
- Policy Advocacy: FDA Commissioner Marty Makary stated in Washington that the agency plans to push for more prescription drugs to become over-the-counter (OTC) this year, aiming to improve drug accessibility and reduce healthcare costs, which could allow patients to obtain basic safe medications without a doctor's visit.
- Regulatory Streamlining: Legislation passed by Congress in November simplifies the regulatory process for transitioning prescription drugs to OTC status, including full, conditional, and partial switch pathways, which is expected to accelerate drug availability and enhance patient convenience in medication access.
- Increased Transparency: Makary emphasized that OTC sales would bypass insurers and pharmacy benefit managers, potentially lowering drug prices and increasing transparency, with cash prices for OTC medications possibly being lower than patients' copays for prescription drugs, thereby alleviating financial burdens on patients.
- Industry Pushback: The pharmaceutical industry has raised concerns about this policy, arguing that OTC drugs may not be covered by insurance, leading to higher costs for patients, and that the FDA lacks authority over drug pricing, necessitating thorough consultations with manufacturers before any transitions.
See More
Perrigo to Release Q4 and FY 2025 Financial Results
- Earnings Release Schedule: Perrigo Company plans to issue its Q4 and FY 2025 financial results on February 26, 2026, indicating the company's commitment to transparency and investor communication.
- Conference Call Details: Following the earnings release, Perrigo will host a conference call at 8:30 A.M. EST, providing a live webcast to ensure investors receive timely key information, thereby enhancing market confidence.
- Replay Service: A taped replay of the call will be available starting at 12:00 P.M. EST on February 26 until midnight on March 5, allowing investors who cannot participate live to access the information, further improving information accessibility.
- Company Background: Perrigo is a leading consumer health company focused on the OTC self-care market, leveraging its strong brand portfolio and unique business model to drive growth and meet consumer needs.
See More
Perrigo to Release Q4 and FY 2025 Financial Results
- Earnings Release Schedule: Perrigo Company plans to announce its fourth quarter and fiscal year 2025 financial results on February 26, 2026, reflecting its ongoing performance in the consumer health products sector.
- Conference Call Details: Following the earnings release, Perrigo will host a conference call at 8:30 A.M. EST, allowing investors to engage through live webcast or phone, enhancing investor relations.
- Replay Availability: A taped replay of the call will be accessible starting at 12:00 P.M. EST on February 26 until midnight on March 5, ensuring that investors who cannot attend live can still access critical information.
- Company Overview: Perrigo is a leading consumer health company focused on the OTC self-care market, leveraging its strong brand and private label offerings to drive continued business growth.
See More
Healthcare Stocks Present Dividend Opportunities Amid Risks
- Perrigo's Value Trap: Perrigo's stock has plummeted by 90% over the past decade, and while it currently offers an 8.2% dividend yield, declining sales and analyst downgrades suggest investors should tread carefully as further price declines may occur.
- Pfizer's Rebound Potential: With a dividend yield of 6.7%, Pfizer faces declining COVID-19 revenues; however, strong growth in non-COVID drugs indicates a potential turnaround, making it a buy opportunity while dividends remain above average.
- Embecta's Turnaround Potential: Embecta's shares have dropped 37% in the past year, yet its 5.5% forward dividend yield and the CEO's optimistic outlook on the GLP-1 product line could present a buying opportunity, potentially improving investor sentiment if initial successes are achieved.
- Attractiveness of Healthcare Sector: While the healthcare sector is considered recession-resistant, investors must remain vigilant against potential yield traps and conduct thorough due diligence to avoid value traps when selecting investment targets.
See More
Perrigo Company Faces Class Action for Misleading Statements
- Class Action Reminder: The Schall Law Firm alerts investors of a class action lawsuit against Perrigo Company for violations of securities laws, concerning securities purchases made between February 27 and November 4, 2025, with a deadline to contact the firm by January 16, 2026.
- False Statement Allegations: The complaint alleges that Perrigo failed to adequately invest in repairs and operational optimization for the baby formula business acquired from Nestlé, leading to materially misleading public statements that misrepresented cost estimates to investors.
- Market Reaction: As the market became aware of Perrigo's actual situation, investor losses significantly increased, highlighting the company's major failures in information disclosure, which could adversely affect its future stock performance.
- Legal Consultation Opportunity: The Schall Law Firm offers free consultations and encourages affected investors to reach out to understand their rights, emphasizing the firm's focus on securities class actions aimed at helping investors recover losses.
See More
Perrigo Company Faces Class Action Lawsuit for Misleading Statements
- Class Action Reminder: DJS Law Group alerts investors of a class action lawsuit against Perrigo Company for violations of securities laws during the trading period from February 27, 2025, to November 4, 2025, encouraging affected shareholders to contact the firm for potential claims.
- Misleading Statements Exposed: The complaint alleges that Perrigo made false and misleading statements following its acquisition of Nestlé's baby formula business, revealing significant underinvestment in maintenance that forced the company to make substantial remedial investments, thus misleading investors throughout the class period.
- Investor Losses: Shareholders who suffered losses are urged to reach out to DJS Law Group to participate in potential recovery, indicating that the company's mismanagement post-acquisition has adversely affected shareholder returns.
- Commitment to Legal Services: DJS Law Group specializes in securities class actions and corporate governance litigation, emphasizing its dedication to enhancing investor returns through balanced counseling and aggressive advocacy, showcasing its expertise and commitment to client interests.
See More
FDA Pushes for Prescription Drugs to Become Over-the-Counter
- Policy Advocacy: FDA Commissioner Marty Makary stated in Washington that the agency plans to push for more prescription drugs to become over-the-counter (OTC) this year, aiming to improve drug accessibility and reduce healthcare costs, which could allow patients to obtain basic safe medications without a doctor's visit.
- Regulatory Streamlining: Legislation passed by Congress in November simplifies the regulatory process for transitioning prescription drugs to OTC status, including full, conditional, and partial switch pathways, which is expected to accelerate drug availability and enhance patient convenience in medication access.
- Increased Transparency: Makary emphasized that OTC sales would bypass insurers and pharmacy benefit managers, potentially lowering drug prices and increasing transparency, with cash prices for OTC medications possibly being lower than patients' copays for prescription drugs, thereby alleviating financial burdens on patients.
- Industry Pushback: The pharmaceutical industry has raised concerns about this policy, arguing that OTC drugs may not be covered by insurance, leading to higher costs for patients, and that the FDA lacks authority over drug pricing, necessitating thorough consultations with manufacturers before any transitions.
See More
Perrigo to Release Q4 and FY 2025 Financial Results
- Earnings Release Schedule: Perrigo Company plans to issue its Q4 and FY 2025 financial results on February 26, 2026, indicating the company's commitment to transparency and investor communication.
- Conference Call Details: Following the earnings release, Perrigo will host a conference call at 8:30 A.M. EST, providing a live webcast to ensure investors receive timely key information, thereby enhancing market confidence.
- Replay Service: A taped replay of the call will be available starting at 12:00 P.M. EST on February 26 until midnight on March 5, allowing investors who cannot participate live to access the information, further improving information accessibility.
- Company Background: Perrigo is a leading consumer health company focused on the OTC self-care market, leveraging its strong brand portfolio and unique business model to drive growth and meet consumer needs.
See More
Perrigo to Release Q4 and FY 2025 Financial Results
- Earnings Release Schedule: Perrigo Company plans to announce its fourth quarter and fiscal year 2025 financial results on February 26, 2026, reflecting its ongoing performance in the consumer health products sector.
- Conference Call Details: Following the earnings release, Perrigo will host a conference call at 8:30 A.M. EST, allowing investors to engage through live webcast or phone, enhancing investor relations.
- Replay Availability: A taped replay of the call will be accessible starting at 12:00 P.M. EST on February 26 until midnight on March 5, ensuring that investors who cannot attend live can still access critical information.
- Company Overview: Perrigo is a leading consumer health company focused on the OTC self-care market, leveraging its strong brand and private label offerings to drive continued business growth.
See More
Healthcare Stocks Present Dividend Opportunities Amid Risks
- Perrigo's Value Trap: Perrigo's stock has plummeted by 90% over the past decade, and while it currently offers an 8.2% dividend yield, declining sales and analyst downgrades suggest investors should tread carefully as further price declines may occur.
- Pfizer's Rebound Potential: With a dividend yield of 6.7%, Pfizer faces declining COVID-19 revenues; however, strong growth in non-COVID drugs indicates a potential turnaround, making it a buy opportunity while dividends remain above average.
- Embecta's Turnaround Potential: Embecta's shares have dropped 37% in the past year, yet its 5.5% forward dividend yield and the CEO's optimistic outlook on the GLP-1 product line could present a buying opportunity, potentially improving investor sentiment if initial successes are achieved.
- Attractiveness of Healthcare Sector: While the healthcare sector is considered recession-resistant, investors must remain vigilant against potential yield traps and conduct thorough due diligence to avoid value traps when selecting investment targets.
See More
Perrigo Company Faces Class Action for Misleading Statements
- Class Action Reminder: The Schall Law Firm alerts investors of a class action lawsuit against Perrigo Company for violations of securities laws, concerning securities purchases made between February 27 and November 4, 2025, with a deadline to contact the firm by January 16, 2026.
- False Statement Allegations: The complaint alleges that Perrigo failed to adequately invest in repairs and operational optimization for the baby formula business acquired from Nestlé, leading to materially misleading public statements that misrepresented cost estimates to investors.
- Market Reaction: As the market became aware of Perrigo's actual situation, investor losses significantly increased, highlighting the company's major failures in information disclosure, which could adversely affect its future stock performance.
- Legal Consultation Opportunity: The Schall Law Firm offers free consultations and encourages affected investors to reach out to understand their rights, emphasizing the firm's focus on securities class actions aimed at helping investors recover losses.
See More
Perrigo Company Faces Class Action Lawsuit for Misleading Statements
- Class Action Reminder: DJS Law Group alerts investors of a class action lawsuit against Perrigo Company for violations of securities laws during the trading period from February 27, 2025, to November 4, 2025, encouraging affected shareholders to contact the firm for potential claims.
- Misleading Statements Exposed: The complaint alleges that Perrigo made false and misleading statements following its acquisition of Nestlé's baby formula business, revealing significant underinvestment in maintenance that forced the company to make substantial remedial investments, thus misleading investors throughout the class period.
- Investor Losses: Shareholders who suffered losses are urged to reach out to DJS Law Group to participate in potential recovery, indicating that the company's mismanagement post-acquisition has adversely affected shareholder returns.
- Commitment to Legal Services: DJS Law Group specializes in securities class actions and corporate governance litigation, emphasizing its dedication to enhancing investor returns through balanced counseling and aggressive advocacy, showcasing its expertise and commitment to client interests.
See More
